Ruxolitinib-Loaded Imprinted Polymeric Drug Reservoir for the Local Management of Post-Surgical Residual Glioblastoma Cells
(1) Background: The current limitations of glioblastoma (GBM) chemotherapy were addressed by developing a molecularly imprinted polymer (MIP)-based drug reservoir designed for the localized and sustained release of ruxolitinib (RUX) within the tumor post-resection cavity, targeting residual infiltra...
Main Authors: | Alexandra-Iulia Bărăian, Bogdan-Cezar Iacob, Olga Sorițău, Ioan Tomuță, Lucia Ruxandra Tefas, Lucian Barbu-Tudoran, Sergiu Șușman, Ede Bodoki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Polymers |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4360/15/4/965 |
Similar Items
-
In Vivo Applications of Molecularly Imprinted Polymers for Drug Delivery: A Pharmaceutical Perspective
by: Alexandra-Iulia Bărăian, et al.
Published: (2022-11-01) -
Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review
by: Jona F. Houthuys, et al.
Published: (2022-12-01) -
Aberrations of Genomic Imprinting in Glioblastoma Formation
by: Anna Lozano-Ureña, et al.
Published: (2021-03-01) -
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
by: Eylem Eliaçık, et al.
Published: (2015-05-01) -
Efficacy of topical ruxolitinib for cutaneous dermatomyositis
by: Aviya Lanis, MD, et al.
Published: (2024-03-01)